Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q1 2024 ▲▼ | Q2 2024 ▲▼ | Change ▲▼ | Q1 2024 ▲▼ | Q2 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Arcellx, Inc. COMMON STOCK | 2,346,630 | 2,346,630 | 0 | $163.21M | $129.51M | 40.55% | -$33.70M |
| CRISPR Therapeutics AG(CRSP) | 1,048,951 | 1,048,951 | 0 | $71.50M | $56.65M | 17.74% | -$14.84M |
| ARS Pharmaceuticals, Inc.(SPRY) | 4,012,903 | 4,012,903 | 0 | $41.01M | $34.15M | 10.69% | -$6.86M |
| Alumis Inc. | 0 | 1,959,896 | +1,959,896 | $0 | $26.07M | 8.16% | +$26.07M |
| Mineralys Therapeutics, Inc.(MLYS) | 2,016,822 | 2,016,822 | 0 | $26.04M | $23.60M | 7.39% | -$2.44M |
| Design Therapeutics, Inc.(DSGN) | 6,526,476 | 6,526,476 | 0 | $26.30M | $21.86M | 6.85% | -$4.44M |
| Nkarta, Inc.(NKTX) | 3,333,333 | 3,333,333 | 0 | $36.03M | $19.70M | 6.17% | -$16.33M |
| enGene Holdings Inc. COM | 0 | 500,000 | +500,000 | $0 | $4.71M | 1.48% | +$4.71M |
| KALA BIO, Inc.(KALA) | 0 | 443,661 | +443,661 | $0 | $3.15M | 0.98% | +$3.15M |